Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Regeneron Pharmaceuticals, Inc.

REGN ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$781.49

▼ -1.48%

Market Cap $80.46B · Vol 194.82K

Key Metrics

P/E Ratio

19.12

FWD: 13.04

Market Cap

$80.46B

Large Cap

Div Yield

0.47%

Quarterly dividend

EPS Growth

+24.12%

YoY

RSI (14)

35.27

Momentum

Beta

0.15

vs Market

52W High

$858.01

8.92% below

52W Low

$541.00

44.45% above

Volume

194.82K

Avg 252.30K

P/B

2.61

Price-to-book

ROE

16.13%

Return on equity

Free Float

97.85%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Regeneron Pharmaceuticals, Inc. (REGN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does REGN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.35%

-1.95%

+27.80%

+0.88%

YTD

+1.25%

+37.54%

-6.16%

+20.14%

Financials & Valuation

TTM · Annual

Total Revenue	$14.34B
Net Income	$4.55B
Revenue Growth (YoY)	+16.73%
Gross Margin	86.56%
Operating Margin	27.02%
Net Profit Margin	31.72%
ROE	16.13%
ROA · ROIC	13.36% · 13.76%

P/E Ratio	19.12
Forward P/E (FY1)	13.04
PEG Ratio	1.99
P/S	5.84
P/B	2.61
P/FCF	22.26
EPS Growth	+24.12%
Outstanding Shares	102.95M

Technical Indicators

50-Day SMA	$751.46
200-Day SMA	$733.53
RSI (14)	35.27
Beta	0.15
52-Week High	$858.01
52-Week Low	$541.00

Volume Today	194.82K
Avg Daily Volume (30D)	252.30K
Relative Volume	0.77x
Volatility (10D)	30.59
Volatility (30D)	27.13
Free Float	97.85%

Analyst Consensus

BUY

Current Price $781.49

Mean Target $839.61

52W Low$541.00 52W High$858.01

Current

Target

$541.00 $858.01

Current Analyst target

+7.44% upside potential · 30 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S6PX49

ISINUS75886F1075

CountryUSA

Sub-IndustryBiopharmaceuticals

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

CSL.AX CSL Limited -1.42% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. -0.56% UCB.BR Ucb SA +1.93% BIIB Biogen Inc. +0.80% INCY Incyte Corp -1.47%

Company Profile

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.